文献速递心力衰竭与心肌病

非奈利酮降低慢性肾脏病合并2型糖尿病患者新发心力衰竭风险:FIGARO-DKD试验分析

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
PubMed 文献 · Circulation · 2021-11-13

本研究基于FIGARO-DKD试验的预设分析,纳入7352例2型糖尿病合并白蛋白尿性慢性肾脏病患者,随机接受非奈利酮或安慰剂。结果显示非奈利酮显著降低新发心力衰竭风险(1.9% vs 2.8%;HR 0.68,95%CI 0.50-0.93;P=0.0162),并改善多项心衰结局,且不受基线心衰病史影响。

要点

  • 非奈利酮降低首次心衰住院风险29%(HR 0.71)。
  • 心衰获益不受基线心衰病史影响。

核心结论

  • 在慢性肾脏病合并2型糖尿病患者中,非奈利酮减少新发心力衰竭并改善其他心衰结局,无论基线有无心衰病史。

研究设计与样本

  • FIGARO-DKD试验的预设分析,纳入7352例2型糖尿病合并白蛋白尿性慢性肾脏病患者,随机接受非奈利酮或安慰剂。

主要发现

  • 新发心衰发生率非奈利酮组1.9% vs 安慰剂组2.8%(HR 0.68,95%CI 0.50-0.93;P=0.0162)。
  • 心血管死亡或首次心衰住院风险降低18%(HR 0.82,95%CI 0.70-0.95;P=0.011)。
  • 首次心衰住院风险降低29%(HR 0.71,95%CI 0.56-0.90;P=0.0043)。
  • 总心衰住院率降低30%(率比0.70,95%CI 0.52-0.94)。
  • 非奈利酮对心衰结局的改善作用不受基线心衰病史影响。

临床怎么用

  • 对于2型糖尿病合并白蛋白尿性慢性肾脏病患者,可考虑使用非奈利酮以降低新发心衰及心衰住院风险。

局限性

  • 治疗中出现的不良事件发生率在两组间均衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease and type 2 diabetes are independently associated with heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) and FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease) trials, finerenone (a selective, nonsteroidal mineralocorticoid receptor antagonist) improved cardiovascular outcomes in patients with albuminuric chronic kidney disease and type 2 diabetes. These prespecified analyses from FIGARO-DKD assessed the effect of finerenone on clinically important HF outcomes. METHODS: Patients with type 2 diabetes and albuminuric chronic kidney disease (urine albumin-to-creatinine ratio ≥30 to <300 mg/g and estimated glomerular filtration rate ≥25 to ≤90 mL per min per 1.73 m2, or urine albumin-to-creatinine ratio ≥300 to ≤5000 mg/g and estimated glomerular filtration rate ≥60 mL per min per 1.73 m2), without symptomatic HF with reduced ejection fraction, were randomized to finerenone or placebo. Time-to-first-event outcomes included new-onset HF (first hospitalization for HF [HHF] in patients without a history of HF at baseline); cardiovascular death or first HHF; HF-related death or first HHF; first HHF; cardiovascular death or total (first or recurrent) HHF; HF-related death or total HHF; and total HHF. Outcomes were evaluated in the overall population and in prespecified subgroups categorized by baseline HF history (as reported by the investigators). RESULTS: Overall, 7352 patients were included in these analyses; 571 (7.8%) had a history of HF at baseline. New-onset HF was significantly reduced with finerenone versus placebo (1.9% versus 2.8%; hazard ratio [HR], 0.68 [95% CI, 0.50-0.93]; P=0.0162). In the overall population, the incidences of all HF outcomes analyzed were significantly lower with finerenone than placebo, including an 18% lower risk of cardiovascular death or first HHF (HR, 0.82 [95% CI, 0.70-0.95]; P=0.011), a 29% lower risk of first HHF (HR, 0.71 [95% CI, 0.56-0.90]; P=0.0043) and a 30% lower rate of total HHF (rate ratio, 0.70 [95% CI, 0.52-0.94]). The effects of finerenone on improving HF outcomes were not modified by a history of HF. The incidence of treatment-emergent adverse events was balanced between treatment groups. CONCLUSIONS: The results from these FIGARO-DKD analyses demonstrate that finerenone reduces new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, irrespective of a history of HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02545049.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Filippatos, Anker, Agarwal, et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2021. PMID: 34775784. doi:10.1161/CIRCULATIONAHA.121.057983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。